These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28770705)

  • 1. Are the cutaneous manifestations in patients with primary antiphospholipid syndrome a marker for predicting lung manifestations?
    Kontic M; Stojanovich L; Mijailović-Ivković M; Velinović M; Srnka J; Zdravkovic M
    Clin Exp Rheumatol; 2018; 36(1):56-61. PubMed ID: 28770705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study.
    Stojanovich L; Kontic M; Djokovic A; Marisavljevic D; Ilijevski N; Stanisavljevic N; Mikovic Z; Petkovic M; Kovcin V
    Clin Exp Rheumatol; 2013; 31(2):234-42. PubMed ID: 23306109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between non-thrombotic neurological and cardiac manifestations in patients with antiphospholipid syndrome.
    Stojanovich L; Kontic M; Smiljanic D; Djokovic A; Stamenkovic B; Marisavljevic D
    Clin Exp Rheumatol; 2013; 31(5):756-60. PubMed ID: 23899875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cutaneous manifestations are significantly related to cerebrovascular in a Serbian cohort of patients with Hughes syndrome.
    Stojanovich L; Djokovic A; Stanisavljevic N; Zdravkovic M
    Lupus; 2018 Apr; 27(5):858-863. PubMed ID: 29301476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary events in antiphospholipid syndrome: influence of antiphospholipid antibody type and levels.
    Stojanovich L; Kontic M; Djokovic A; Ilijevski N; Stanisavljevic N; Marisavljevic D
    Scand J Rheumatol; 2012 May; 41(3):223-6. PubMed ID: 22324785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiphospholipid-mediated thrombosis: interplay between type of antibodies and localisation of lung, and cardiovascular incidences in primary antiphospholipid syndrome.
    Stojanovich L; Djokovic A; Kontic M
    Clin Exp Rheumatol; 2015; 33(4):531-6. PubMed ID: 26088955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort.
    Djokovic A; Stojanovich L; Stanisavljevic N; Djokic S; Filipovic B; Matic P; Milanovic M; Apostolovic S; Saponjski J
    Clin Rheumatol; 2022 May; 41(5):1447-1455. PubMed ID: 35018582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between cerebrovascular and valvular manifestations in a Serbian cohort of patients with antiphospholipid syndrome.
    Djokovic A; Stojanovich L; Stanisavljevic N; Banicevic S; Smiljanic D; Milovanovic B
    Clin Exp Rheumatol; 2018; 36(5):850-855. PubMed ID: 29846156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association?
    Sahin M; Duzgun N; Tunc SE; Tutkak H
    Clin Rheumatol; 2007 Feb; 26(2):154-60. PubMed ID: 16598413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiphospholipid syndrome (APS) primary (PAPS) and secondary (SAPS)].
    Chwalińska-Sadowska H; Meissner M; Wudarski M; Zabek J; Wojciechowska B
    Pol Arch Med Wewn; 2006 May; 115(5):401-6. PubMed ID: 17195351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Serbian Primary Antiphospholipid Syndrome Patients Confirmed a Strong Association Between Livedo Reticularis and Arterial Thrombosis: A National Cross-Sectional Cohort Study.
    Djokovic A; Stojanovich L; Stanisavljevic N; Matic P; Colic D; Skrijelj D; Djokic S; Filipovic B
    J Clin Rheumatol; 2022 Oct; 28(7):362-366. PubMed ID: 35697016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study.
    Stojanovich L; Markovic O; Marisavljevic D; Elezovic I; Ilijevski N; Stanisavljevic N
    Lupus; 2012 Mar; 21(3):338-45. PubMed ID: 21993381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome.
    Hoxha A; Ruffatti A; Mattia E; Meneghel L; Tonello M; Salvan E; Pengo V; Punzi L
    Clin Chem Lab Med; 2015 Jul; 53(8):1265-70. PubMed ID: 25562605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous manifestations of antiphospholipid antibody syndrome.
    Weinstein S; Piette W
    Hematol Oncol Clin North Am; 2008 Feb; 22(1):67-77, vi. PubMed ID: 18207066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome.
    Bećarević M; Stojanović L; Ignjatović S; Dopsaj V
    Clin Rheumatol; 2016 May; 35(5):1361-5. PubMed ID: 26971791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome.
    Mattia E; Ruffatti A; Tonello M; Meneghel L; Robecchi B; Pittoni M; Gallo N; Salvan E; Teghil V; Punzi L; Plebani M
    Clin Chem Lab Med; 2014 Sep; 52(9):1329-33. PubMed ID: 24651022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development].
    Fischer K; Brzosko M; Walecka A; Ostanek L; Sawicki M
    Pol Arch Med Wewn; 2007; 117 Suppl():13-7. PubMed ID: 18778013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dermatologic manifestations of the antiphospholipid syndrome].
    Francès C; Barete S; Soria A
    Rev Med Interne; 2012 Apr; 33(4):200-5. PubMed ID: 22078802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?
    Detkov ; Gil-Aguado A; Lavilla P; Cuesta MV; Fontán G; Pascual-Salcedo D
    Lupus; 1999; 8(6):430-8. PubMed ID: 10483010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.